FDA Approves Ofatumumab Combination To Treat Relapsed CLL

September 2, 2016

The U.S. Food and Drug Administration (FDA) approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).  Based on a phase II clinical trial, ofatumumab in combination with fludarabine and cyclophosphamide led to longer progression free survival for patients than fludarabine and cyclophosphamide alone. Read more here.

To learn more about leukemia and cancer treatment visit My PearlPoint or The Leukemia & Lymphoma Society